TenderAi Logo

Discover the latest tenders, get AI-powered insights, and collaborate to seize government opportunities with TenderAI.

Contact Us

✉️ contact@tenderai.in📞 +91-8448770364

Departments

View All
Department of Military Affairs(90827)
Department of Defence Production(20910)
Indian Railways(14280)
Department of Heavy Industry(10115)
Department of Atomic Energy(10071)

States

View All
MAHARASHTRA(20071)
UTTAR PRADESH(18984)
JAMMU & KASHMIR(12651)
GUJARAT(11830)
KARNATAKA(9749)

Cities

View All
MUMBAI(6104)
BANGALORE(5435)
HYDERABAD(3403)
PUNE(3272)
JAMMU(2591)
Privacy Policy|Terms of Service

© 2025 TenderAI. All rights reserved.

medcrave biomedicals private limited Tender Performance & Track Record

CIN: U33300MH2021PTC365970
Active
Private
Company limited by shares

medcrave biomedicals private limited

Tender Performance & Track Record

CIN: U33300MH2021PTC365970
Active
Private
Company limited by shares

Company Overview

Summary
Government Tender Analysis: MEDCRAVE BIOMEDICALS PRIVATE LIMITED MEDCRAVE BIOMEDICALS PRIVATE LIMITED is a dynamic player in the Indian government procurement landscape, specializing in medical equipment and actively participating in tenders across various ministries and departments. TenderAI's analysis reveals a strong performance, particularly in Maharashtra, with significant wins in Rural Development and Panchayat Raj Department tenders.
Primary Ministry: N/APrimary Department: Rural Development and Panchayat Raj Department Maharashtra
Founded: 2021State: MAHARASHTRA
Primary Ministry:
N/A
Primary Department:
Rural Development and Panchayat Raj Department Maharashtra
Founded:2021
State:MAHARASHTRA

Tender Performance

Data for 01 April 2024 to 18 June 2025

Live Data

Total Bids / Contract Value

Bids3
Value₹4.35Cr

Qualified Bids / Q Rate

Bids3
Q Rate100.0%

Total Wins / Win Value

Win2
Value₹4.17Cr

Wins Rate / Q-W Rate

Rate66.7%
Q-W Rate66.7%

Detailed Performance Analysis

Scroll to view more categories

Top Bid Competitors

Companies that frequently compete with you in the same tenders — ranked by their total win value.You applied for 3 bids — MEDIMARK DIAGNOSTICS PRIVATE LIMITED appeared in 2 of them.

Company
Total Bids
Value
Qualified
Rate
Wins
Value

MEDCRAVE BIOMEDICALS PRIVATE LIMITED

Your Company
66.7% win rate
3
₹4.35 Cr
3
100.0%
2
₹4.17 Cr

MEDCRAVE BIOMEDICALS PRIVATE LIMITED

Your Company
Total Bids
3
₹4.35 Cr
Qualified
3
100.0%
Wins
2
₹4.17 Cr
66.7% win rate
MEDIMARK DIAGNOSTICS PRIVATE LIMITED
50.0% win rate
2
₹1.99 Cr
2
100.0%
1
₹17.99 Lakh
MEDIMARK DIAGNOSTICS PRIVATE LIMITED
Total Bids
2
₹1.99 Cr
Qualified
2
100.0%
Wins
1
₹17.99 Lakh
50.0% win rate
RGB HEALTHCARE PRIVATE LIMITED
0.0% win rate
2
₹4.17 Cr
2
100.0%
0
₹0
RGB HEALTHCARE PRIVATE LIMITED
Total Bids
2
₹4.17 Cr
Qualified
2
100.0%
Wins
0
₹0
0.0% win rate
GIBZ SOLUTIONS PRIVATE LIMITED
0.0% win rate
1
₹17.99 Lakh
1
100.0%
0
₹0
GIBZ SOLUTIONS PRIVATE LIMITED
Total Bids
1
₹17.99 Lakh
Qualified
1
100.0%
Wins
0
₹0
0.0% win rate
BALAJI PHARMA
0.0% win rate
1
₹2.36 Cr
0
0.0%
0
₹0
BALAJI PHARMA
Total Bids
1
₹2.36 Cr
Qualified
0
0.0%
Wins
0
₹0
0.0% win rate
SHRI ENTERPRISES.
0.0% win rate
1
₹2.36 Cr
1
100.0%
0
₹0
SHRI ENTERPRISES.
Total Bids
1
₹2.36 Cr
Qualified
1
100.0%
Wins
0
₹0
0.0% win rate
Company Profile
CINU33300MH2021PTC365970
Class
Private
Status
Active
Founded2021

Financial Details

Authorized Capital₹5.0L
Paid-up Capital₹1.0L

Registered Office

Shop No 26 Chandresh Kaveri Apt,Lodha Heavan Nilje,DombivliNA-THANE-Maharashtra-421204-India

Industry Classification

Manufacturing (Machinery & Equipments)

NIC Code33300

Company Type

CategoryCompany limited by shares
Sub-CategoryNon-government company
Origin
Indian

Market Information

Listing Status
Unlisted
ROCROC Mumbai
Free Trial!

Transform Your Tender Process

Join thousands of businesses winning more tenders

No Credit Card Required
0%
Success Rate
0x
Faster Process
0/7
24/7 Support

Smart Alerts

Get AI-powered tender recommendations

Market Intel

Track competitor bidding patterns

Email Reports

Weekly detailed analytics reports

Download Hub

Export tender data in bulk format

Smart Tracking

Never miss important deadlines

& Much More...

Discover all premium features with your trial

DS

"TenderAI transformed our bidding process. We've increased our win rate by 40% and saved countless hours."

Dipanshu Sahijpal • Supernirman
Start 15-Day Free Trial
Secure & Trusted
24/7 Support
Easy Setup

Historical Performance

7-year trend analysis (2018-2025)

Historical Data

Company Overview (1 Apr 2018-31 Mar 2025))

Total Bids

11

Qualified: 7
Q Rate: 63.6%

Contract Value

₹3.98 Cr

Avg. Bid: ₹70.31 Lakh
Avg. EMD: ₹0

L1 Bids

4

Win Rate: 36.4%
Q to W Ratio: 57.1%

Recent Win Rate

50.0%

Change: +50.0%
Period: FY 2024-25

Performance Analytics

Last 7 Years
Performance Trend
Win/Loss Distribution
Contract Value Growth Over Time

Government Tender Analysis: MEDCRAVE BIOMEDICALS PRIVATE LIMITED

MEDCRAVE BIOMEDICALS PRIVATE LIMITED is a dynamic player in the Indian government procurement landscape, specializing in medical equipment and actively participating in tenders across various ministries and departments. TenderAI's analysis reveals a strong performance, particularly in Maharashtra, with significant wins in Rural Development and Panchayat Raj Department tenders.

Key Performance Indicators (KPIs) from April 1, 2018, to March 31, 2025:

  • Overall Win Rate: 36.4% (11 bids, 4 wins)
  • FY2024-25 Win Rate: 50% (2 bids, 1 win) demonstrating a significant improvement
  • Total Contract Value: ₹3,97,88,207.0 (April 1, 2018 - March 31, 2025)
  • FY2024-25 Contract Value: ₹2,54,21,786.0
  • Qualification Rate: 63.6% (7 out of 11 bids qualified)
  • TenderAI Financial Health Score: 72.8 (Rated as Good)

The company's financial health is considered good, reflecting a positive trajectory and strong market positioning, despite inconsistent yearly performance. MEDCRAVE BIOMEDICALS shows significant strength in winning high-value tenders, particularly within the Ministry of Health and Family Welfare and Rural Development sectors in Maharashtra. However, consistent performance across fiscal years needs attention.